Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma

Sumit Madan, Martha Lacy, Angela Dispenzieri, Morie Gertz, Francis Buadi, Suzanne R. Hayman, Kristen Detweiler-Short, David M Dingli, Steven Zeldenrust, John Lust, Philip R. Greipp, S Vincent Rajkumar, Shaji K Kumar

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The efficacy of retreatment with immunomodulatory drugs (IMiDs) among patients with multiple myeloma who received this class of drugs for initial therapy is unknown. We studied 140 patients who received either thalidomide-dexamethasone (81; 58%) or lenalidomide-dexamethasone (59; 42%) as first-line therapy of multiple myeloma followed by repeat IMiD (thalidomide [34; 24%] or lenalidomide [106; 76%]) as one of the salvage regimens. A median of 2 treatments (range, 1-6), including a stem cell transplant in 105 patients (75%), were administered before IMiD-based salvage therapy. The median time from diagnosis to repeat exposure to IMiD was 28 months. Among the 113 evaluable patients, 50 (44%) achieved at least a partial response, and 63 (56%) achieved less than a partial response to repeat IMiD. Response rates with lenalidomide retreatment were higher than with repeat administration of thalidomide.

Original languageEnglish (US)
Pages (from-to)1763-1765
Number of pages3
JournalBlood
Volume118
Issue number7
DOIs
StatePublished - Aug 18 2011

Fingerprint

Retreatment
Thalidomide
Multiple Myeloma
Salvaging
Dexamethasone
Pharmaceutical Preparations
Transplants
Stem cells
Salvage Therapy
Therapeutics
Stem Cells
Drug Therapy
lenalidomide

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. / Madan, Sumit; Lacy, Martha; Dispenzieri, Angela; Gertz, Morie; Buadi, Francis; Hayman, Suzanne R.; Detweiler-Short, Kristen; Dingli, David M; Zeldenrust, Steven; Lust, John; Greipp, Philip R.; Rajkumar, S Vincent; Kumar, Shaji K.

In: Blood, Vol. 118, No. 7, 18.08.2011, p. 1763-1765.

Research output: Contribution to journalArticle

Madan, Sumit ; Lacy, Martha ; Dispenzieri, Angela ; Gertz, Morie ; Buadi, Francis ; Hayman, Suzanne R. ; Detweiler-Short, Kristen ; Dingli, David M ; Zeldenrust, Steven ; Lust, John ; Greipp, Philip R. ; Rajkumar, S Vincent ; Kumar, Shaji K. / Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. In: Blood. 2011 ; Vol. 118, No. 7. pp. 1763-1765.
@article{bcf142991d7f4160a6e88a4c62c0cdb4,
title = "Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma",
abstract = "The efficacy of retreatment with immunomodulatory drugs (IMiDs) among patients with multiple myeloma who received this class of drugs for initial therapy is unknown. We studied 140 patients who received either thalidomide-dexamethasone (81; 58{\%}) or lenalidomide-dexamethasone (59; 42{\%}) as first-line therapy of multiple myeloma followed by repeat IMiD (thalidomide [34; 24{\%}] or lenalidomide [106; 76{\%}]) as one of the salvage regimens. A median of 2 treatments (range, 1-6), including a stem cell transplant in 105 patients (75{\%}), were administered before IMiD-based salvage therapy. The median time from diagnosis to repeat exposure to IMiD was 28 months. Among the 113 evaluable patients, 50 (44{\%}) achieved at least a partial response, and 63 (56{\%}) achieved less than a partial response to repeat IMiD. Response rates with lenalidomide retreatment were higher than with repeat administration of thalidomide.",
author = "Sumit Madan and Martha Lacy and Angela Dispenzieri and Morie Gertz and Francis Buadi and Hayman, {Suzanne R.} and Kristen Detweiler-Short and Dingli, {David M} and Steven Zeldenrust and John Lust and Greipp, {Philip R.} and Rajkumar, {S Vincent} and Kumar, {Shaji K}",
year = "2011",
month = "8",
day = "18",
doi = "10.1182/blood-2011-04-350009",
language = "English (US)",
volume = "118",
pages = "1763--1765",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma

AU - Madan, Sumit

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Gertz, Morie

AU - Buadi, Francis

AU - Hayman, Suzanne R.

AU - Detweiler-Short, Kristen

AU - Dingli, David M

AU - Zeldenrust, Steven

AU - Lust, John

AU - Greipp, Philip R.

AU - Rajkumar, S Vincent

AU - Kumar, Shaji K

PY - 2011/8/18

Y1 - 2011/8/18

N2 - The efficacy of retreatment with immunomodulatory drugs (IMiDs) among patients with multiple myeloma who received this class of drugs for initial therapy is unknown. We studied 140 patients who received either thalidomide-dexamethasone (81; 58%) or lenalidomide-dexamethasone (59; 42%) as first-line therapy of multiple myeloma followed by repeat IMiD (thalidomide [34; 24%] or lenalidomide [106; 76%]) as one of the salvage regimens. A median of 2 treatments (range, 1-6), including a stem cell transplant in 105 patients (75%), were administered before IMiD-based salvage therapy. The median time from diagnosis to repeat exposure to IMiD was 28 months. Among the 113 evaluable patients, 50 (44%) achieved at least a partial response, and 63 (56%) achieved less than a partial response to repeat IMiD. Response rates with lenalidomide retreatment were higher than with repeat administration of thalidomide.

AB - The efficacy of retreatment with immunomodulatory drugs (IMiDs) among patients with multiple myeloma who received this class of drugs for initial therapy is unknown. We studied 140 patients who received either thalidomide-dexamethasone (81; 58%) or lenalidomide-dexamethasone (59; 42%) as first-line therapy of multiple myeloma followed by repeat IMiD (thalidomide [34; 24%] or lenalidomide [106; 76%]) as one of the salvage regimens. A median of 2 treatments (range, 1-6), including a stem cell transplant in 105 patients (75%), were administered before IMiD-based salvage therapy. The median time from diagnosis to repeat exposure to IMiD was 28 months. Among the 113 evaluable patients, 50 (44%) achieved at least a partial response, and 63 (56%) achieved less than a partial response to repeat IMiD. Response rates with lenalidomide retreatment were higher than with repeat administration of thalidomide.

UR - http://www.scopus.com/inward/record.url?scp=80051869676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051869676&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-04-350009

DO - 10.1182/blood-2011-04-350009

M3 - Article

C2 - 21673347

AN - SCOPUS:80051869676

VL - 118

SP - 1763

EP - 1765

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -